NASDAQ
90.22USD
+0.80 (+0.89%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
8B
P/E
—
EPS
—
Beta
0.55
52W range
19.9-91.57
Day range
88.22–91.28
Open
89.94
Prev close
89.42
Volume
553K
Avg volume
1.9M
Dividend
0.00
IPO
2018-07-26
https://www.zacks.com/stock/news/2960456/3-low-beta-stocks-to-minimize-portfolio-risk-lqda-et-pbf?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rw-2960456 · 7/24/2026+1.00
https://www.zacks.com/stock/news/2957861/can-lqda-s-differentiated-pah-strategy-drive-long-term-growth?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2957861 · 7/22/2026+1.00
https://www.fool.com/coverage/etfs/2026/07/05/ihe-vs-pjp-which-pharmaceutical-etf-is-the-better-buy-for-investors/ · 7/5/2026+0.00
https://www.gurufocus.com/news/8906318/liquidia-corp-lqda-stock-up-34-and-still-undervalued-gf-score-75100 · 6/8/2026+0.60
https://www.zacks.com/commentary/2919457/new-strong-buy-stocks-for-may-13th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions-2919457 · 5/13/2026+1.00
https://www.fool.com/coverage/filings/2026/04/05/liquidia-s-chairman-sold-company-shares-worth-usd2-5-million-should-investors-avoid-the-stock/ · 4/5/2026+0.80
https://www.fool.com/coverage/filings/2026/03/28/the-chief-commercial-officer-of-liquidia-lqda-sold-80-000-shares-for-usd2-8m/ · 3/28/2026+0.60
https://www.zacks.com/commentary/2883847/4-biotech-stocks-to-watch-for-potential-upside-in-2026?cid=CS-STOCKNEWSAPI-FT-industry_outlook-2883847 · 3/13/2026+0.80
https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51101305/liquidia-analysts-boost-their-forecasts-after-q4-earnings · 3/6/2026+0.40
https://seekingalpha.com/article/4859975-liquidia-corporation-lqda-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript · 1/15/2026+0.20
https://www.defenseworld.net/2025/12/13/awh-capital-l-p-takes-866000-position-in-liquidia-corporation-lqda.html · 12/13/2025+0.20
https://www.zacks.com/stock/news/2794858/wall-street-analysts-see-a-51-15-upside-in-liquidia-corporation-lqda-can-the-stock-really-move-this-high?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2794858 · 11/24/2025+0.80
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
